NCT00661739View on ClinicalTrials.gov

A Multicentre Phase I-II Study to Investigate the Combination of Bendamustine With Weekly Paclitaxel as First or Second Line Therapy in Patients With Metastatic Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

September 30, 2010

Study Completion Date

May 31, 2011

Conditions
Metastatic Breast Cancer
Interventions
DRUG

Bendamustine

Dose-level Bendamustine(mg/m²): I:50; II:60; III:60; IV:70; V:70 Dose-level Paclitaxel (mg/m²): I:60; II:60; III:80; IV:80; V:90 Treatment will be given on day 1,8,15 and repeated on day 29. When the recommended dose has been determined a total of 48 pts will be treated at this dose level.

All Listed Sponsors
lead

GBG Forschungs GmbH

OTHER

NCT00661739 - A Multicentre Phase I-II Study to Investigate the Combination of Bendamustine With Weekly Paclitaxel as First or Second Line Therapy in Patients With Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter